Adult patients with CML in chronic phase with typical BCR::ABL1 transcripts, stable deep molecular response (MR4.5 IS) for two years, and no previous resistance were eligible. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.